Costs of neoadjuvant chemotherapy and surgery in patients with liver metastases from advanced colorectal cancer

Publisher Website
Google Scholar
Abstract
SummaryLiver metastases are found in 40-70% of patients with colorectal cancer. Surgery is the only treatment for liver metastases that gives potential for long-term survival. Studies with oxaliplatin combination therapy have reported significant reduction of tumour bulk in the liver, allowing resection, with curative intent, of previously unresectable liver metastases.This study uses a simple decision model to estimate average chemotherapy costs and surgical costs of treating advanced colorectal cancer patients with metastases confined to the liver with either oxaliplatin combination therapy, or 5-FU/FA alone. The incremental cost per life-year gained with oxaliplatin combination therapy ranged between £5,489 and £15,624, and treatment could enable between 7.3% and 17.5% extra patients to be resected and therefore gain the chance of long-term survival compared to 5-FU/FA treatment alone. To date, oxaliplatin combination therapy is the only first-line treatment that has shown the possibility of long-term ...